2015
Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Yeboa D, Aneja S, Montana G, Roberts K, Yu J. Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. Journal Of Radiation Oncology 2015, 4: 11-17. DOI: 10.1007/s13566-015-0182-y.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProstate cancerRadiation therapyEnd Results (SEER) databaseAmerican Joint CommitteeBreast cancer treatmentUse of RTInitial therapyMethodsThe SurveillanceRT receiptNonmetastatic patientsResults databaseCommon malignancyTherapy utilizationColorectal cancerLung cancerPrevalent malignancyCancer sitesRadiotherapy useHigh incidenceMedical treatmentJoint CommitteeDisease sitesPersistent decreaseTherapy
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differencesProton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy
Yu J, Soulos P, Herrin J, Cramer L, Potosky A, Roberts K, Gross C. Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s13. DOI: 10.1016/j.ijrobp.2012.07.040.Peer-Reviewed Original ResearchProton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationThe influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapyThe influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management. Journal Of Clinical Oncology 2012, 30: 108-108. DOI: 10.1200/jco.2012.30.5_suppl.108.Peer-Reviewed Original ResearchHealth service areasOnly surgical treatmentSurgical treatmentHealth system characteristicsProstate cancer managementTreatment choiceCancer managementRadiation oncologistsRadiation oncologist densityEnd Results (SEER) databaseSeparate logistic regression modelsHealth system dataLogistic regression modelsArea Resource FileUse of RTUrologist densityHospital densityPatient factorsResults databaseSurgical interventionUrology serviceTreatment modalitiesProstate cancerNCI's SurveillanceRadiation therapy
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate glandTesticular Doses in Image-Guided Radiotherapy of Prostate Cancer
Deng J, Chen Z, Yu JB, Roberts KB, Peschel RE, Nath R. Testicular Doses in Image-Guided Radiotherapy of Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e39-e47. PMID: 21489702, DOI: 10.1016/j.ijrobp.2011.01.071.Peer-Reviewed Original ResearchConceptsImage-guided radiotherapyTesticular dosesFull-fan modeProstate cancerFemoral headLess doseCBCT scansHalf-fan modeProstate cancer patientsKilovoltage cone-beamCancer patientsIntensity-modulated radiotherapy (IMRT) treatmentKilovoltage CBCTSuperior-inferior directionCone beamDosesCBCT fieldProstate patientsRectumDoseProstateMore doseRadiotherapy treatmentPatientsRadiotherapy
2007
On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy
Chen ZJ, Deng J, Roberts K, Nath R. On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2007, 70: 303-310. PMID: 17980500, PMCID: PMC2289996, DOI: 10.1016/j.ijrobp.2007.09.007.Peer-Reviewed Original ResearchConceptsDose reductionProstate brachytherapyDose compensationLarge edemaBiochemical recurrence-free survivalRecurrence-free survivalSignificant dose reductionEffects of edemaSublethal damage repairAdditional irradiationPrescription doseProstate cancerIndividual patientsEdemaEdema evolutionPrescribed doseProstate edemaEffective doseRadiobiologic effectsBrachytherapyDoseProstate implantsDose responseImplants
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer